The earliest blood vessels in mammalian embryos are formed when endothelial cells differentiate from angioblasts and coalesce into tubular networks. Thereafter, the endothelium is thought to expand solely by proliferation of pre-existing endothelial cells. Here we show that a complementary source of endothelial cells is recruited into pre-existing vasculature after differentiation from the earliest precursors of erythrocytes, megakaryocytes and macrophages, the erythro-myeloid progenitors (EMPs) that are born in the yolk sac. A first wave of EMPs contributes endothelial cells to the yolk sac endothelium, and a second wave of EMPs colonizes the embryo and contributes endothelial cells to intraembryonic endothelium in multiple organs, where they persist into adulthood. By demonstrating that EMPs constitute a hitherto unrecognized source of endothelial cells, we reveal that embryonic blood vascular endothelium expands in a dual mechanism that involves both the proliferation of pre-existing endothelial cells and the incorporation of endothelial cells derived from haematopoietic precursors.
Blood vessels distribute oxygen, nutrients, hormones and immune cells through the vertebrate body and help to remove waste molecules. Accordingly, the formation of functional blood vessels during embryogenesis is a prerequisite for vertebrate life. Endothelial cells (ECs) form the inner lining of blood vessels; they first arise from mesenchymal precursors termed angioblasts on embryonic day (E)7.0 in mice 1 . After condensing into the yolk sac vasculature and paired dorsal aortae, ECs proliferate within existing endothelium to increase vascular diameter, sprout into avascular tissue areas or remodel into smaller vessels by intussusceptive growth 1 . The current consensus is therefore that embryonic ECs are a self-contained cell lineage that expands without contribution from new angioblasts or circulating precursors. By contrast, circulating endothelial progenitors have been proposed to exist in adult vertebrates, although their relationship to myeloid cells remains controversial 2 .
In addition to their primary roles in the innate immune system, myeloid cells such as monocytes and macrophages also modulate vascular growth 3 . For example, the tissue-resident macrophages of the embryonic mouse brain, termed microglia, contact ECs at the tips of neighbouring vessel sprouts to promote their anastomosis into perfused vessel loops 4 . By contrast, no direct contribution of myeloid cells to embryonic vascular endothelium has been reported; thus, genetic lineage tracing with myeloid Vav or Lyz2 (also known as Lysm) promoters does not mark embryonic blood vascular endothelium in mice 5, 6 .
Most tissue-resident macrophages arise from EMPs that form in the extra-embryonic yolk sac during embryogenesis and also serve as precursors for erythrocytes and megakaryocytes 7−11 . In mice, an early wave of EMPs, also referred to as primitive haematopoietic progenitors, buds from the yolk sac endothelium between E7.0 and E8. 25 and differentiates by E9.0 without monocytic intermediates into yolk sac macrophages 7,10,12−14 . These macrophages colonize the embryo proper to generate tissue-resident macrophages, such as microglia in the brain or Langerhans cells in the epidermis 13 . A later wave of EMPs buds from the yolk sac endothelium from E8.25 onwards and colonizes the liver after the embryonic circulation has been established 7, 8, 11, 14, 15 . These later-born EMPs expand in the liver into monocytes that subsequently differentiate into tissue-resident macrophages in many organs except the brain 7, 13 .
Csf1r lineage tracing identifies an EC subset
To target early EMPs 7,10,12 , microglia 16, 17 and other differentiated myeloid cells 18 , we and others have used a transgene that expresses CRE recombinase under the promoter for the myeloid lineage gene Csf1r (also known as Fms), which encodes the colony-stimulating factor 1 receptor CSF1R. Microglia appear as single YFP + cells in hindbrains from Csf1r-iCre mouse embryos carrying the Rosa Yfp recombination reporter, with microglia and ECs also stained for isolectin B4 (IB4) 16 ( Fig. 1a ). As previously shown 4 , the number of IB4 + YFP + microglia peaked in the hindbrain subventricular zone at E11.5, when vessels fuse into the subventricular vascular plexus (SVP) (Fig. 1b ). Unexpectedly, we also observed sporadic, elongated IB4 + YFP + cells that appeared bound into the endothelium and increased steadily in number during SVP expansion ( Fig. 1a-c ; Extended Data Fig. 1a ). Csf1r-iCre targeting of vessel-bound cells was not an artefact caused by spontaneous Rosa Yfp recombination or unspecific immunostaining, because littermates that did not carry Csf1r-iCre lacked YFP staining (Fig. 1a ). Furthermore, hindbrain imaging from mice carrying Csf1r-iCre with CAG-Cat-Egfp or Rosa tdTom as alternative recombination reporters confirmed targeting of both microglia and vessel-bound elongated cells (Extended Data Fig. 1b, c) . The tamoxifen-induced activation of CRE, expressed from an independently generated Csf1r-Mer-iCre-Mer transgene that targets myeloid cells 19 , also targeted vessel-bound cells in addition to microglia (Fig. 1d ). Corroborating the endothelial identity of Csf1r-iCre-targeted, elongated vessel-bound cells, these cells expressed the EC markers ERG and PECAM1, had a similar morphology to ECs targeted with the endothelium-specific Cdh5-CreER T2 transgene, formed junctions with neighbouring ECs via the endothelial cadherin CDH5 and lacked both myeloid and pericyte markers ( Fig. 1e, Extended Data Fig. 1d-f ).
Csf1r-iCre-mediated EC targeting was not explained by Csf1r expression in brain ECs, because hindbrain ECs, unlike microglia, lacked expression of a Csf1r-Egfp transgene that faithfully reports Csf1r promoter activity 20, 21 and accordingly did not contain CSF1R protein Article reSeArcH (Extended Data Fig. 2a, b ). Moreover, our analysis of published transcriptomic datasets 22 showed that Csf1r is not expressed in ECs from embryonic brain, liver or lung, whilst quantitative PCR with reverse transcription (RT-qPCR) analysis of tdTomato + ECs isolated by fluorescence-activated cell sorting (FACS) confirmed that they expressed Cdh5, but not Csf1r or the myeloid gene Spi1, which encodes the PU.1 transcription factor (Extended Data Fig. 2c -g). The lack of endothelial Csf1r expression suggests that Csf1r-iCre-targeted brain ECs arise from precursors in which Csf1r is activated before their incorporation into hindbrain vasculature. These precursors cannot be differentiated myeloid cells such as microglia, whose formation is PU.1-dependent 4 , because PU.1 deficiency did not reduce the number of Csf1r-iCre-targeted ECs in the hindbrain at E11.5 ( Fig. 1f -h) or the striatum at postnatal day (P)0 (Extended Data Fig. 2h ). We therefore investigated whether Csf1r-iCre-targeted ECs are derived from PU.1independent, Csf1r-expressing precursors.
Csf1r lineage-traced ECs derive from EMPs
As EMPs are PU.1-independent 23 , we investigated whether the formation of Csf1r-iCre-targeted ECs was spatiotemporally linked to the emergence of Csf1r-expressing EMPs from yolk sac haemogenic endothelium, which was visualized by staining for the EC marker VEGFR2. At E8.5, yolk sacs from Csf1r-Egfp embryos contained clusters of round EGFP + VEGFR2 + cells that protruded from the endothelium into the vascular lumen ( Fig. 2a ), consistent with previous work showing that FACS-isolated EMPs express both Csf1r 7 and Vegfr2 9 , and that EMPs bud from the yolk sac endothelium 11 . Csf1r-iCre lineage tracing in yolk sacs at E8.5 similarly identified round YFP + cells that protruded into the vascular lumen, expressed VEGFR2, persisted in PU.1-deficient yolk sacs and expressed the EMP marker KIT 7 (Fig. 2b, c ; Extended Data Fig. 3a, b ). Even though EGFP expression could not be detected in Csf1r-Egfp yolk sac endothelium ( Fig. 2a KIT expression (Extended Data Fig. 3b ), showing that they were not haemogenic ECs 24 . Similar to Csf1r-iCre-targeted hindbrain ECs, the lineage-traced yolk sac ECs were PU.1-independent ( Fig. 2b, c ). The finding that EMP formation correlates with the emergence of Csf1r-iCre-targeted yolk sac ECs was corroborated by temporally restricted Csf1r-Mer-iCre-Mer-mediated lineage tracing. As tamoxifeninduced, CRE-mediated reporter recombination peaks approximately 6 h and ends 24 h after tamoxifen injection 25 , we activated Csf1r-Mer-iCre-Mer;Rosa tdTom in discrete temporal windows by single injections at E8.5, E9.5 or E10.5 before identifying lineage-traced cells in E12.5 yolk sacs (Extended Data Fig. 3c ). Induction at all three stages labelled yolk sac macrophages (Extended Data Fig. 3d ), consistent with their origin from Csf1r-expressing EMPs 7 and their maintenance of Csf1r expression 10, 12 . In addition, induction at E8.5 or E9.5 yielded tdTomato + ECs, whereas induction at E10.5 did not (Extended Data Fig. 3d ). As EMPs are present in the yolk sac at E8.5 and E9.5, but move to the liver thereafter 13 , their local availability makes them plausible precursors of Csf1r-iCre-labelled yolk sac ECs. Consistent with this, tamoxifen induction of a Kit CreERT2 knock-in allele at E8.5, when KIT + early EMPs are still present in the yolk sac 7 , lineage-traced both yolk sac ECs and macrophages (Extended Data Fig. 3e, f) .
In contrast to early wave EMPs that remain in the yolk sac, the late wave EMPs that populate the embryo are reported to lack Csf1r expression, at least when they form in the yolk sac 7 . We therefore investigated whether late wave EMPs begin to express Csf1r after homing to the liver and whether they are the precursors of the Csf1r-iCre-targeted ECs that appear in the hindbrain from E10.5 onwards. Thus, we combined the Csf1r-Egfp expression reporter with Csf1r- Mer were injected with a single dose of tamoxifen on the indicated days before whole-mount staining of E12.5 hindbrains for the indicated markers and imaging including tdTomato fluorescence; n = 3 independent experiments each. Arrows, tdTomato + ECs; arrowheads, microglia; the clear arrowhead indicates lack of ERG expression in microglia; wavy arrows, cluster of tdTomato + ERG − IB4 − neural cells derived from Kit + neural progenitors. Scale bars, 20 µm. Article reSeArcH induced CRE-mediated recombination at E10.5; 24 h later, we used FACS to separate the differentiated myeloid cells from EMPs and EMPderived myeloid progenitors 7 contained in the liver or blood ( Fig. 3a, b) . The differentiated myeloid cell populations from both sources contained tdTomato + EGFP + cells, as expected, but tdTomato + EGFP + cells were also present in the EMP/myeloid progenitor populations from both liver and blood ( Fig. 3a, b ; Extended Data Fig. 3g -i). These findings suggest that a subset of intraembryonic EMPs expresses Csf1r and can access organs such as the hindbrain via the circulation.
To determine whether the intraembryonic presence of Csf1rexpressing late wave EMPs correlated with the emergence of Csf1r-iCre-targeted hindbrain ECs, we visualized tdTomato expression in hindbrains from E12.5 Csf1r-Mer-iCre-Mer;Rosa tdTom mice after tamoxifen induction at E8.5, E9.5 or E10.5 (Fig. 3c ). The hindbrain vasculature contained tdTomato + ECs following induction at E10.5, but not at E8.5 or E9.5, even though the Csf1r-expressing microglia were targeted at all stages ( Fig. 3d ). Kit CreERT2 induction at E8.5 also caused microglia targeting ( Fig. 3e , f), consistent with microglia arising from yolk sac macrophages generated at around E8.5 from KIT + early wave EMPs 7 . Induction of Kit CreERT2 at E8.5, when late wave EMPs begin to arise in the yolk sac 7 , also yielded tdTomato + ECs in the hindbrain at E12.5 (Fig. 3e , f), confirming that yolk sac-born EMPs can give rise to intraembryonic ECs. Lineage tracing from three independent Cre alleles therefore suggests that EMPs give rise to both yolk sac and hindbrain ECs.
Csf1r-expressing EMPs give rise to ECs in vitro
The myeloid and erythroid potential of EMPs has been demonstrated through in vitro differentiation 11, 26 . Using similar assays, we compared the endothelial potential of FACS-isolated differentiated myeloid cell and EMP/myeloid progenitor populations from E12.5 Csf1r-iCre;Rosa tdTom liver and blood, while ensuring that we were excluding contamination by PECAM1 + ECs (Fig. 4a, b ). Both cell populations were mostly tdTomato + (Fig. 4c, d ). As expected 7 , the EMP-containing population comprised round cells with a large nucleus and little cytoplasm, whereas the myeloid cell population contained granulocytes, in addition to monocytes in the liver and macrophages in the blood (Fig. 4c, d ). For cell culture, we used methocult to promote the formation of haematopoietic colonies, but included a fibronectin substrate to facilitate EC differentiation. Differentiated myeloid cells persisted in these cultures as single round or amoeboid cells ( Fig. 4e , f) that were tdTomato + ERG low VEGFR2 low (Fig. 4g , h; antibody controls in Extended Data Fig. 4a, b ). By contrast, both liver and blood EMPs formed myeloid and erythroid cell colonies in suspension ( Fig. 4e , f) and additionally gave rise to single adherent cells that appeared spindle-shaped, were tdTomato + ERG high VEGFR2 high and lacked myeloid cell markers, consistent with an EC identity ( Fig. 4g, h ; Extended Data Fig. 4c ). Together, these experiments demonstrate that EMPs have endothelial potential alongside their known haematopoietic capacity.
Csf1r lineage ECs support blood vessel growth
Hoxa cluster genes modulate haematopoiesis 27 and are upregulated in perinatal ECs compared to adult ECs 28 (Fig. 5a ); HOXA9 also promotes EC differentiation from progenitors in ischaemic disease in adults 29 . Our analysis of published transcriptomic data 9, 30 revealed that Hoxa transcripts are enriched in E10.25 EMPs compared to E9.0 EMPs and macrophages ( Fig. 5a ). To investigate whether Hoxa deficiency impairs the formation of EMP-derived hindbrain ECs, we combined Csf1r-iCre with a conditional null Hoxa cluster mutation (Hoxa fl ) (Extended Data Fig. 5a ). Gene copy analysis showed effective gene targeting in KIT + cells from Csf1r-iCre;Hoxa fl/fl mutants at E12.5 compared to control livers, but the number of liver CD45 + cells, including differentiated myeloid cells, was not reduced (Extended Data Fig. 5b-f ). Hoxa genes are therefore dispensable for myeloid cell specification from late wave EMPs. By contrast, fewer tdTomato + ECs, also derived from late wave EMPs, had formed in Rosa tdTom -carrying Csf1r-iCre;Hoxa fl/fl mutant hindbrains compared to control hindbrains; moreover, SVP complexity was reduced in mutant hindbrains ( Fig. 5b-d ). Although we observed 20% fewer microglia in mutant hindbrains than in control hindbrains (Extended Data Fig. 5g -i), this is not likely to have contributed to the vascular defect, because even a 50% microglia reduction in Csf1 op/+ mutants did not reduce SVP complexity (Extended Data Fig. 5j -l). Together, these findings suggest that Hoxa cluster genes promote the formation of EMP-derived brain ECs, which in turn support normal brain vascular development.
Transcriptional signature of Csf1r lineage ECs
Csf1r-iCre-targeted ECs not only appeared morphologically similar to neighbouring ECs ( Fig. 1 ), but also had similarly slow proliferation and overall cell cycle kinetics (Extended Data Fig. 6 ). Moreover, RNA sequencing (RNA-seq) analysis of FACS-isolated tdTomato + and tdTomato − ECs from E12.5 Csf1r-iCre;Rosa tdTom embryos showed that they had largely similar transcriptomes, with only a few differentially expressed genes, including the expected difference in the tdTomato transcript ( Fig. 6a-c ; Extended Data Fig. 7a ). Corroborating their endothelial identity, tdTomato + ECs lacked markers for differentiated myeloid cells and other non-EC lineages, but expressed core EC transcripts at similar levels to tdTomato − ECs (Fig. 6d, e ). Amongst the differentially expressed genes, markers typical of EC specialization, such as ephrins and EPH receptors regulating arteriovenous differentiation, were under-represented in tdTomato + ECs (Fig. 6e ). This observation is consistent with Csf1r-iCre-targeted ECs being derived from progenitors that are recruited into preformed vascular endothelium. Whereas brain EC markers (for example, Slc2a1) were under-represented in the embryo-wide tdTomato + EC population, liver EC markers (for example, Oit3, Mrc1) were over-represented, including early markers of liver sinusoidal differentiation (Stab2, Lyve1) 31 (Fig. 6c a, Transcriptomic analysis of the indicated cell populations for the indicated genes, based on published RNA-seq 9 and microarray data 30 Article reSeArcH liver vasculature. Immunostaining and FACS of Csf1r-iCre;Rosa tdTom E12.5 and E18.5 embryos confirmed that tdTomato + ECs were more prevalent than tdTomato − ECs in liver endothelium (Fig. 6g, i ; Extended Data Figs. 8, 9a, b ). As liver EC specialization markers were present in both tdTomato − and tdTomato + liver ECs at E12.5 ( Fig. 6g ; Extended Data Fig. 8a ), liver ECs from two distinct origins appear to undergo similar organ-specific EC differentiation.
Csf1r lineage ECs persist in multiple adult organs
Immunostaining and FACS analyses at E12.5 and E18.5 showed that Csf1r-iCre-targeted ECs were also present in the heart and lung vasculature at similar levels to the brain ( Fig. 6i ; Extended Data Figs. 8, 9a, b). Corresponding immunostaining and FACS analyses showed that tdTomato + ECs persisted in the brain, heart, lung and liver of adults and continued to dominate the adult liver sinusoidal endothelium ( Fig. 6h, j; Extended Data Figs. 9c, 10a ). Accordingly, all adult organs examined contained EMP-derived ECs.
Discussion
The heterogeneous origin of blood vascular mural cells from distinct populations of mesodermal progenitors, haematopoietic and neural crest cells has been established 32 . Here we have shown that embryonic Fig. 6 | The Csf1r-iCre-targeted EC population has a core endothelial transcription signature with an increase in liver EC transcripts and persists in adult organs. a-f, Transcriptomic analysis. a, FACS strategy to isolate tdTomato − and tdTomato + ECs from E12.5 Csf1r-iCre;Rosa tdTom embryos for RNA-seq. b, Graphic representation of genes for which expression was significantly different (green dots) or similar (black dots) between both EC populations. c, Volcano plot of significantly differentially expressed transcripts with more than 100 counts per transcript; selected genes are named; grey and red data points represent transcripts in tdTomato − ECs with at least twofold over-or under-representation, respectively. d-f, Relative expression levels for markers typical of myeloid (Cx3cr1-Ptprc), astrocytic (Gfap), smooth muscle (Acta2), neuronal (Rbfox3, Nefl), skeletal muscle (Myog) or epithelial (Cdh1) differentiation (d), for EC core and maturation markers (e) and for representative brain and liver EC specialization markers compared to brain versus liver/lung ECs microarrays 30 (f); mean ± s.d.; RNA-seq, n = 3 embryos (DESeq2;
Benjamini-Hochberg's multiple comparisons test for P value adjustment, P adj ); microarray, n = 5 organs (two-way ANOVA, Bonferroni's multiple comparisons test); NS, not significant, *P < 0.05, **P < 0.01, ***P < 0.0001; see Source Data for exact values. g, h, Csf1r-iCre;Rosa tdTom E12.5 (g) and adult (h) liver cryosections, labelled for the indicated markers and RFP to visualize tdTomato, including DAPI counterstaining in h; n = 3 independent experiments. Arrows, tdTomato + ECs; arrowheads, macrophages; clear arrowheads indicate that macrophages lack VEGFR2. Scale bar, 50 µm. i, j, FACS of Csf1r-iCre;Rosa tdTom E12.5 (i) and adult (j) brain, heart, lung and liver to determine their relative tdTomato + EC contributions; mean ± s.d.; n = 5 organs each (i; except lung, n = 4), n = 6 organs each (j; except liver, n = 7); each data point represents one organ; ***P < 0.0001 (i); **P = 0.0023, 0.0066, 0.00541 (j) for liver versus brain, heart, lung, respectively (one-way ANOVA with Tukey's multiple comparisons test).
Article reSeArcH vascular endothelium has two major origins. Thus, ECs emerge via a classical pathway of angioblast differentiation into ECs and the pathway described in this report, which entails differentiation of ECs from the EMP lineage (Extended Data Fig. 10b ). Multiple previous investigations have used Csf1r-iCre together with recombination reporters to follow the embryonic myeloid lineage 7,10,12 . These studies predominantly used FACS with haematopoietic markers, which precluded observation of Csf1r-iCre-targeted ECs. By contrast, we included EC markers in FACS protocols to additionally isolate Csf1r-iCre-targeted ECs. In addition, immunostaining was previously used to identify Csf1r-iCre-targeted cells in the retina 17 , liver and colon 18 , but without description of EC targeting, possibly because of the close spatial proximity of ECs and perivascular macrophages 4, 33 . We overcame this limitation by performing high-resolution imaging of tissues immunostained with both EC and myeloid cell markers. The contribution of EMP-derived ECs to the yolk sac, brain, heart and lung vasculature is proportionally smaller than that of ECs of classical origin, whereas EMP-derived ECs predominate in the liver, particularly the sinusoidal endothelium. Liver endothelium was previously reported to be heterogeneous in origin, with an endoderm lineage contribution of approximately 15% and the remainder of the liver EC population attributed to a venous origin 34 . Our results suggest that liver endothelium contains approximately 60% EMP-derived ECs. Preferential homing of EMPs to the liver after their entry into the embryonic circulation 13 , and the dependence of liver growth on rapid vascular expansion 35 , may explain the relatively large contribution of EMP-derived ECs to this organ. Ultimately, the discovery that EMPs provide a source of ECs for organ vasculature may open up new therapeutic avenues for vessel-dependent organ repair and regeneration. For example, EMPs or EMP-like EC progenitors, derived from human stem cells by modulating the expression of factors such as Hoxa genes, might be delivered systemically to support vascular growth in ischaemic diseases or to provide angiocrine signals that stimulate tissue stem cells.
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MEthodS
Mouse strains. All animal procedures were performed in accordance with the institutional Animal Welfare Ethical Review Body (AWERB) and UK Home Office guidelines. To obtain mouse embryos of defined gestational age, mice were paired in the evening and the presence of a vaginal plug the following morning was defined as E0.5. In some studies, we analysed adult mice, defined as more than eight weeks of age. Mice carrying the Csf1r-iCre transgene 18 were mated to mice carrying the Cre recombination reporters Rosa Yfp (ref. 36 ), Rosa tdTom (ref. 37 ) or CAG-cat-Egfp (ref. 38 ). PU.1 +/− mice 39 were mated to Rosa Yfp mice and then Csf1r-iCre mice to obtain Csf1r-iCre;Rosa Yfp ;Pu.1 −/− embryos that lacked differentiated myeloid cells including microglia 4, 39, 40 as well as the myeloid cell precursors of skin pericytes 41 . Hoxa fl/fl mice 42 were mated to Rosa tdTom mice and then Csf1r-iCre mice to obtain Csf1r-iCre;Rosa tdTom ;Hoxa fl/fl embryos. Csf1r-Mer-iCre-Mer (ref. 19 ) and Kit CreERT2 (ref. 43 ) as well as endothelial-specific Cdh5-CreER T2 (refs 41, 44 ) mice were mated to Rosa tdTom mice. In some experiments, mice carrying the Csf1r-Egfp-Ngfr/Fkbp1a/Tnfrsf6 (short: Csf1r-Egfp) reporter of Csf1r expression 21 were mated to Csf1r-Mer-iCre-Mer;Rosa tdTom mice. We also used mice with a heterozygous loss of function mutation in Csf1 (Csf1 +/op ) 45 . All mouse strains were maintained on a mixed background (C57Bl6/J;129/Sv), with the exception of Csf1r-Mer-iCre-Mer, which was maintained on a mixed FVB:C57/Bl6 background. For tamoxifen induction of CRE activity, tamoxifen (Sigma) was dissolved in peanut oil and administered via a single intraperitoneal injection into each pregnant dam. For Csf1r-Mer-iCre-Mer induction, we injected 1 mg tamoxifen; to achieve mosaic Cdh5-Cre-ER T2 activation, we injected 20 µg tamoxifen; for Kit CreERT2 induction at E8.5, we injected 3 mg tamoxifen together with 1.75 mg progesterone to increase induction without inducing abortions (Sigma). Immunolabelling. Samples were fixed in 4% formaldehyde in PBS and processed as whole-mounts or dehydrated in sucrose and embedded in optimal cutting temperature (OCT, Tissue-Tek) compound to cut 20-µm cryosections. Immunolabelling was performed as described previously for whole-mount hindbrains 46 . We used the following antibodies and dilutions: goat anti-CDH5 (1:200; AF1002, lot FQI0116101, R&D Systems), rabbit anti-CSF1R (1:500; sc-692, lot K1212, Santa Cruz), rat anti-EMCN (1:50; sc-65495, lot C2917, Santa Cruz), rabbit anti-ERG (1:200; ab92513, lot GR32027 69-1, Abcam), rat anti-F4/80 (1:500; MCA497R, lot 1605, Serotec), chicken anti-GFP (1:1,000; GFP-1020, lot 0511FP12, Aves) and rabbit anti-GFP (1:500; 598, lot 079, MBL) for YFP or EGFP labelling, rabbit anti-IBA1 (1:500; 019-19741, Wako Chemicals), rat anti-KIT (1:500; 553353, lot 30259, BD Pharmingen), rabbit anti-NG2 (1:200; AB5320, lot 2726769, Millipore), rat anti-PECAM1 (1:200; 553370, lot 5205656, BD Pharmingen), rabbit anti-pHH3 (1:400; 06-570, lot 2825969, Millipore), rabbit anti-RFP (1:1,000; PM005, lot 045, MBL), goat anti-VEGFR2 (1:200; AF644, lot COA0417021, R&D Systems). Secondary antibodies used included Alexa Fluor-conjugated goat antichick, -rabbit or -rat IgG (Life Technologies), or, for primary antibodies raised in goat, donkey fluorophore-conjugated FAB fragments of anti-chick, -goat, -rabbit or -rat IgG (Jackson ImmunoResearch). Note that CDH5 47 , ERG 48 , EMCN 49 , PECAM1 50 and VEGFR2 51 were used as EC markers, whereas F4/80 52 and IBA1 53 were used as macrophage markers and NG2 54 as a pericyte marker. Biotinylated IB4 (L2140, lot 085M4032V, Sigma) followed by Alexa-conjugated streptavidin (ThermoFisher) was also used to detect brain ECs and microglia 4, 16 . Nuclei were labelled with DAPI. Images were acquired with a LSM710 laser scanning confocal microscope (Zeiss) and processed using LSM image browser (Zeiss) and Photoshop CS4 (Adobe) software. Three-dimensional reconstructions including surface rendering and the generation of virtual slices for lateral views of high-resolution confocal z-stacks was performed using Imaris (Bitplane). Z-stack projections of confocal images are shown unless indicated otherwise in the figure legends. FACS and cell culture. Tissues were mechanically and enzymatically homogenized in RPMI1640 with 2.5% fetal bovine serum (ThermoFisher), 100 µg/ml collagenase/dispase (Roche), 50 µg/ml DNase (Qiagen) and 100 µg/ml heparin (Sigma), incubated for 5 min with 0.5 mg/ml rat Fc block (Becton Dickinson) and labelled with a combination of PE/Cy7-conjugated rat anti-PECAM1 (clone 390, cat 102418, lot B212262), FITC-conjugated rat anti-CD45 (clone 30-F11, cat 103108, lot B246762) or CD41 (clone MWReg30, cat 133903, lot B201955), APC-conjugated rat anti-KIT (clone 2B8, cat 105812, lot B217855) and PerCp/ Cy5.5-conjugated rat anti-CD11b (clone M1/70, cat 101227) (all BioLegend). Appropriate fluorescence gating parameters were established with unstained tissue, Csf1r-iCre-or Csf1r-Egfp-negative tissues and fluorescence-minus-one (FMO) staining. For cell cycle analysis, cell populations were incubated with 10 µg/ml Hoechst 33342 (Sigma) for 30 min at 37 °C 55 before labelling with PE/Cy7-conjugated rat anti-PECAM1 and performing FACS analysis. In all experiments, doublets were eliminated using pulse geometry gates (FSC-H versus FSC-A and SSC-H versus SSC-A), whereas dead cells were removed using SYTOX Blue (Life Technologies) or LIVE/DEAD Fixable Violet (Life Technologies). Single-cell suspensions were analysed using the BD LSRFortessa X-20 cell analyser or sorted using the BD Influx cell sorter (BD Biosciences); FlowJo software (FlowJo LLC) was used for subsequent analyses. In some experiments, a fraction of each population was cytospun onto a glass slide for Wright-Giemsa staining (Sigma) followed by imaging using an LSM510 microscope equipped with an AxioCam MRc camera (Zeiss). For cell culture experiments, cell populations were sorted into DMEM with 100 U/ml penicillin, 100 U/ml streptomycin and 20% fetal bovine serum (all ThermoFisher) before seeding the cells into a 96-well plate coated with 10 µg/ml fibronectin (ThermoFisher) to facilitate EC differentiation. Cells were then cultured in methocult (STEMCELL Technologies) to promote the formation of haematopoietic colonies, which were imaged using a TS100 microscope equipped with a DS-5M colour camera (Nikon). After removal of methocult, adherent cells were fixed with 4% formaldehyde in PBS and then labelled for VEGFR2, ERG, CD45, F4/80 and CSF1R (see above) before imaging using a Ti-E microscope (Nikon). RNA-seq. PECAM1 + CD45 − CD11b − KIT − ECs were isolated from E12.5 Csf1r-iCre;Rosa tdTom embryos and divided into tdTomato + and tdTomato − populations with the BD Influx cell sorter before RNA was extracted with the RNeasy Micro Kit (QIAGEN). cDNA was generated and amplified using the SMART-seq V4 ultra low input RNA kit (Clontech). 100 pg of amplified cDNA per sample was used to prepare a library with the Nextera XT kit (Illumina) and run on the NextSeq 500 sequencer (lllumina). Raw sequence data were pre-processed to trim poor quality base calls and adaptor contamination using Trimmomatic v.0.36.4 56 and aligned to the mouse mm10 genome with STAR v.2.5.2b 57 . Mapped reads were deduplicated to reduce PCR bias using Picard v2.7.1.1 software (http://broadinstitute. github.io/picard/), and the reads-per-transcript were then calculated using FeatureCount v1.4.6.p5 software 58 . Differential expression was performed using the BioConductor package DESeq2 via the SARTools wrapper v1.3.2.0 59 . RT-PCR. We extracted RNA from cells isolated with the BD Influx cell sorter (see above) with the RNeasy Micro Kit for cDNA synthesis with Superscript IV (ThermoFisher). Quantitative (q)RT-PCR was performed with SYBR Green on an HT7900 system (Applied Biosystems) using the following oligonucleotide pairs: Actb 5′-CACCACACCTTCTACAATGAG-3′ and 5′-GTCTCAAACATGA TCTGGGTC-3′; Cdh5 5′-GATGCAGATGACCCCACTGT-3′ and 5′-AGGGCATCTTGTGTTCCAC-3′; Csf1r 5′-TGCGTCTACACAGTTCAGAG-3′ and 5′-ATGCTGTATATGTTCTTCGGT-3′; Spi1 5′-GCCATAGCGATCACTA CTG-3′ and 5′-CAAGGTTTGATAAGGGAAGC-3′; Hoxa11 5′-TCTTTGCCT CTCTCCTTCCTT-3′ and 5′-TTGCAGACGCTTCTCTTTGTT-3′; Evx1 5′-GTGTGCTCTGGGCTCCTGT-3′ and 5′-GCCAGGGTGCCTTGAGAG-3; Slc2a1 5′-CCCCAGAAGGTTATTGAGGAGT and 5′-ACAAAGAGGCCGACAG AGAA; Mrc1 5′-ACTGGGCAATGCAAATGGAG and 5′-CCCTCAAAGTGCAA TGGACA; Oit3 5′-CGTCTGCTTCCATGTCTACTG and 5′-GTGCTCACATTC ATTTTCGTCA. For each oligonucleotide pair, a no-template control reaction was included. Microarray analysis. Published microarray data were used to compare gene expression levels (normalized log 2 OD) in E14.5 CD45 − PECAM1 + brain versus pooled lung and liver ECs (GSE35802) 22 and in HUVECs versus adult retinal ECs (GSE20986) 30 using GEO2R software (NCBI). Statistical analysis. No randomization method was used, because tissues for analysis were allocated to experimental groups according to genotype, gestational age, organ or cell type. To ensure unbiased interpretation of results, the genotype and gestational age were disclosed only after data collection was complete, but the investigators were not blinded to sample origin (organ or cell type). All experiments involving two or more genotypes for comparison included littermate controls, and the minimum sample number was three. No statistical methods were used to predetermine sample size. The number of YFP + ECs and YFP + microglia in Csf1r-iCre;Rosa Yfp hindbrains (Fig. 1a , b, f-h) was determined in three randomly chosen 0.72-mm 2 regions of each whole-mount labelled and flat-mounted hindbrain. For hindbrains in Hoxa-targeting experiments, the number of F4/80 + microglia (Extended Data Fig. 5 ) and tdTomato + and IB4 + volume (Fig. 5b, c) were determined from confocal z-stacks of four randomly chosen 0.18-mm 2 regions on the lateral side of each hindbrain (Extended Data Fig. 5g ). The z-stacks were surface rendered with Imaris (Bitplane) to obtain the F4/80 + , tdTomato + and IB4 + volumes, and the F4/80 + volume was then subtracted from both the IB4 + and tdTomato + total volumes to obtain the IB4 + EC and tdTomato + EC volumes before calculating the ratio of tdTomato + to IB4 + EC volume. To determine the number of vascular intersections in Hoxa-targeting experiments (Fig. 5b,d) , the same confocal z-stacks were analysed with Imaris filament tracer after F4/80 + microglia were masked. For Figs. 1, 5 , all counts obtained from one hindbrain were averaged to yield the value for that hindbrain. For all experiments, we calculated the mean value for at least three independent samples, where error bars represent the standard deviation of the mean (for details, see legends). Comparison of medians against means justified the use of a parametric test; to determine whether two datasets were significantly different, we therefore calculated P values with a two-tailed unpaired Student's t-test; P < 0.05 was considered significant. When more than two datasets were compared, we used the statistical tests indicated in the associated legends. Fig. 1 | Endothelial Csf1r- iCre-targeting is observed with different recombination reporters, and targeted ECs are distinguishable from macrophages and pericytes. a-c, Csf1r-iCre;Rosa Yfp (a), Csf1r-iCre;CAG-Cat-Egfp (b) and Csf1r-iCre;Rosa tdTom (c) hindbrains (n = 3 each) at the indicated stages were whole-mount labelled with IB4 and for YFP (a) or GFP (b) or are shown with tdTomato fluorescence (c). In a, the white squares indicate areas that were imaged at higher magnification for Fig. 1a . The indicated single channels are also shown individually. d, Csf1r-iCre;Rosa tdTom E12.5 hindbrains (n = 3), whole-mount labelled for ERG and CDH5 and shown including tdTomato fluorescence to demonstrate that Csf1r-iCre targets ECs that form junctions with neighbouring non-targeted ECs. e, f, E12.5 Csf1r-iCre;Rosa Yfp hindbrains, labelled for YFP and the microglia marker F4/80 (e) or the pericyte marker NG2 (f) together with IB4, show that Csf1r-iCre-targeted vessel-bound cells are neither microglia nor pericytes; n = 3 each. In e, the boxed area is shown in higher magnification and as single channels adjacent to the panel. In f, a single optical y/z cross section at the position indicated with the yellow line is displayed at higher magnification with single channels. Arrowheads, microglia; arrows, ECs; double arrowheads, pericytes; curved arrow, junctional CDH5 staining; solid and clear symbols indicate the presence or absence of marker expression, respectively. Scale bars: 100 µm (a), 20 µm (b, c, e, f), 50 µm (d).
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Extended Data Fig. 2 | Endothelial Csf1r-iCre-targeting is not caused by endothelial Csf1r expression and occurs independently of myeloid differentiation. a, b, Csf1r-Egfp (a) and Csf1r-iCre;Rosa Yfp (b) E11.5 hindbrains (n = 3 each), whole-mount labelled for CSF1R and EGFP or YFP together with IB4, show lack of Csf1r promoter activity and CSF1R protein in ECs. c, Relative Cdh5 and Csf1r expression levels in our analysis of published E14.5 brain or pooled lung/liver EC microarrays 22 ; n = 5 each; ***P < 0.0001 (two-tailed unpaired t-test). d-g, FACS separation of tdTomato + cells from Csf1r-iCre;Rosa tdTom embryos (n = 3) for gene expression analysis, including representative gating strategy to exclude dead cells and doublets in this and subsequent experiments (d) and sorting into PECAM1 + CD45 − ECs versus CD45 + PECAM1 − MCs (e). 
Extended Data Fig. 4 | Immunostaining controls for cultured Csf1r-iCre-targeted cells. The indicated cell populations were FACS-isolated from E12.5 Csf1r-iCre;Rosa tdTom liver or blood with the indicated markers and cultured for three days in methocult (met.) on fibronectin (FN); n = 1 experiment. a, b, Adherent cells from tdTomato + liver MC (a) and EMP/MP (b) cultures were stained for ERG and VEGFR2 (top) or with secondary antibodies only (bottom). c, Adherent cells from tdTomato + blood EMP and MP cultures were immunostained for CSF1R together with the myeloid markers CD45 (top) or F4/80 (bottom). In the first panel in each row, the phase contrast and DAPI images were merged. In panels 2-4 in each row, immunolabelled cells were visualized together with tdTomato fluorescence, with single channels for the indicated markers shown separately in greyscale. Arrows, tdTomato + ECs; arrowheads, tdTomato + MCs; solid and clear symbols indicate the presence or absence, respectively, of the indicated markers. Scale bars, 20 µm.
Extended Data Fig. 6 | Csf1r-iCre-targeted ECs proliferate in vivo. a, b, E12.5 Csf1r-iCre;Rosa tdTom yolk sac (a) or hindbrain (b), wholemount stained for the proliferation marker pHH3 and VEGFR2 or for pHH3 together with IB4, respectively, and shown together with tdTomato fluorescence (n = 3 each). Areas indicated with white squares were imaged at higher magnification and are shown below the corresponding panels, with tdTomato and pHH3 channels also shown separately in greyscale. Arrows, proliferating tdTomato + pHH3 + ECs; solid and clear symbols indicate the presence or absence, respectively, of tdTomato fluorescence; wavy arrow, a tdTomato − pHH3 + neural progenitor. 
Extended Data Fig. 8 | Csf1r- iCre-targeted ECs contribute to embryonic vasculature in multiple organs. a, 20-µm cryosections of the indicated E12.5 Csf1r-iCre;Rosa tdTom organs (n = 3 each) were immunolabelled for the indicated EC markers together with antibodies for RFP to identify tdTomato protein (top and bottom) or are shown with tdTomato fluorescence (middle); single channels are shown in greyscale. The white boxes indicate the positions of areas shown in higher magnification in Fig. 6g ; some areas selected for higher magnification are not contained entirely within the field of view, and accordingly the boxes are shown incomplete. Scale bars, 200 µm. b, Gating strategy for FACS analysis of tdTomato + and tdTomato − ECs from E12.5 Csf1r-iCre;Rosa tdTom brain, lung, heart and liver versus control organs lacking iCre, using antibodies for CD11b, CD41, CD45, KIT and PECAM1; associated EC quantifications are shown in Fig. 6i . An analogous strategy was used for the quantifications shown in Fig. 6j and in Extended Data A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
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Sample size
Sample sizes were not pre-calculated. For histologial analyses in Figs. 1, 2, 3 and 4, at least three, but typically more, independent samples (i.e. hindbrains or yolk sacs; for n, see figure legends), were qualitatively analysed by immunostaining, with each experimental repeat yielding highly similar results. Tissue culture experiments were repeated three times with independent samples, with qualitative results obtained by histological examination without associated statistical tests, but results from each experiment being highly similar (Fig. 5 ). In some experiments (Fig. 6) , sample sizes were based on prior published protocols (e.g. Fantin et al., Nature Protocols 2013) and analogous experiments carried out with other strains in our lab (e.g. Fantin et al., Blood 2013). In some experiments (Fig. 2) , sample sizes were based on analogous experiments carried out in other genetic background strains in our lab (Fantin et al., Cell Reports 2015) . In other experiments, we found that using three independent samples per group gave us sufficient power to detect significant differences between groups , which were then validated by comparing results to published microarray data (i.e. Fig. 7A -E).
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Replication
We have reproduced all our results in a minimum of three independent experimental repeats and using independent samples (i.e. by using embryonic materials from several litters). Many experiments were repeated independently by two investigators in the lab, in particular experiments shown in Fig. 1, 2 , 3, 4 and 5.
Randomization Randomisation was not required for our study.
Blinding
Genotype determined group allocation. Data analysis were performed by different staff members responsible for genotyping and analysis, respectively, to avoid conscious and unconscious bias.
Reporting for specific materials, systems and methods For all antibodies used, we have provided the catalogue number and supplier. For polyclonal antibodies, which may show batch variation, we have listed the lot number. For monoclonal antibodies, we have listed the clone name.
Validation
All antibodies were sold by the manufacturer with validation data and citations, and they detected the specified targets in our study as expected. Specificity was confirmed by obtaining the expected pattern of tissue staining with the respective antibodies. For example, an antibody to the vascular endothelial protein CDH5 stained only blood vessels, and the F4/80 antibody for macrophages/microglia stained only those cells (e.g. Fig. 1x ). YFP and EGFP staining was validated by comparing tissues expressing these proteins or lacking these proteins based on their genetic status (e.g. see Fig. 1A ).
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We have used laboratory mice for our studies and have reported the strain, genetic background and age for each experiment.
